Danaher Corporation (DHR)

NYSE · Health Care · Diagnostics & Research
By Alex · Tickerpine
$205.79
-1.65 (-0.80%)
Price — last 10 years monthly, dividend-adjusted · hover for detail
Market Cap
$144.67B
P/E (TTM)
37.0
Forward P/E
22.1
EPS (TTM)
$5.56
ROE
7.61%
Profit Margin
15.95%
Revenue Growth
5.50%
Dividend Yield
0.77%
Beta
0.80
52W High
$242.80
52W Low
$160.93
Analyst Target
$227.96

DHR stock forecast: what analysts expect

Consensus rating
Strong Buy
Avg. 12-month target
$227.96
Implied upside
+10.8%

Wall Street analysts covering Danaher Corporation currently rate the stock a Strong Buy on average, with a mean 12-month price target of $227.96 — +10.8% versus the last price of $205.79. Targets reflect analyst opinion, not a guarantee.

What would an investment in DHR be worth today?
Run DHR through our free historical return calculator.
Calculate DHR returns →

DHR historical returns

PeriodTotal returnAnnualized (CAGR)$1,000 grew to
1 year +0.7% +0.7% $1,007
3 years -10.9% -3.8% $891
5 years -26.6% -6.0% $734
10 years +200% +11.6% $3,001
20 years +1,454% +14.7% $15,543
Since 1978 +465,488% +19.4% $4,655,882

Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in DHR.

DHR annual returns by year

2026 YTD -9.7%
2025 +0.4%
2024 -0.3%
2023 -1.2%
2022 -19.0%
2021 +48.6%
2020 +45.3%
2019 +49.6%
2018 +11.8%
2017 +20.0%

Congress trading in DHR

21 members of Congress have disclosed trading DHR — 23 purchases and 12 sales worth an estimated $728,000. Most recent disclosure: Dec 18, 2025.

See who in Congress traded DHR →

About Danaher Corporation

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Company website ↗

DHR Key Statistics

Previous Close$207.44P/E Ratio37.0
Market Cap$144.67BPEG Ratio1.37
Revenue (TTM)$25.11BROE7.61%
Gross Margin58.75%ROA3.95%
Debt / Equity53.0Employees58,000

DHR in plain English

DHR stock: frequently asked questions

What is Danaher Corporation's stock price today?

Danaher Corporation (DHR) last traded at $205.79 on the NYSE. Over the past 52 weeks the stock has traded between $160.93 and $242.80.

Is DHR stock a buy or a sell?

Wall Street analysts' consensus rating on DHR is "Strong Buy", with an average 12-month price target of $227.96 — about +10.8% versus the current price of $205.79. Analyst targets are opinions, not guarantees; always do your own research.

How much would $1,000 invested in DHR 10 years ago be worth today?

A $1,000 investment in Danaher Corporation made 10 years ago would be worth about $3,001 today (dividends reinvested) — a total return of 200%, or 11.6% per year.

Does DHR pay a dividend?

Yes. Danaher Corporation currently pays a dividend yielding about 0.77% per year at today's share price.

What is DHR's P/E ratio?

DHR trades at a trailing price-to-earnings ratio of 37.0, and 22.1 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.

Do members of Congress trade DHR stock?

Yes — 21 members of Congress have disclosed trades in DHR under the STOCK Act, totaling 23 purchases and 12 sales worth an estimated $728,000.

What is Danaher Corporation's ticker symbol?

Danaher Corporation trades under the ticker symbol DHR on the NYSE.

Compare DHR with peers

DHR vs LLYEli Lilly and Company $1,220.28 DHR vs JNJJohnson & Johnson $260.86 DHR vs ABBVAbbVie Inc. $248.76 DHR vs UNHUnitedHealth Group Incorporated $405.59 DHR vs MRKMerck & Company, Inc. $132.92

Data last refreshed from public sources. Figures may be delayed. Not investment advice.